Skip to main content

Eli Lilly and Company Q3 FY2026 results

  • LLY · NYSE
  • Pharmaceuticals
  • S&P 500
$1443.50+1.14%Close 13 Nov 2026 · Market value $1.37T

Eli Lilly and Company reported revenue of $24.4 billion, up 38.6% from a year earlier, net income of $6.45 billion and diluted earnings per share of $7.22 against $6.21 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, filed 29 Oct 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.

Eli Lilly and Company Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$24.40B$17.60B+38.6%
Gross profit$20.46B$14.59B+40.2%
Gross margin83.9%82.9%+1.0 pts
Operating income$8.61B$7.41B+16.1%
Operating margin35.3%42.1%−6.8 pts
Net income$6.45B$5.58B+15.5%
Diluted EPS$7.22$6.21+16.3%
Operating cash flow$11.40B$8.84B+29.0%
Capital expenditure$3.18B$2.09B+52.3%
Free cash flow$8.22B$6.75B+21.8%

Operating KPIs for the quarter

Eli Lilly and Company operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
Cardiometabolic Health revenue$12.4Bup 39.6%
Zepbound revenue$5.3Bup 47.6%
Mounjaro revenue$5.0Bup 40.8%
Oncology revenue$1.5Bup 10.4%
Verzenio revenue$897.0Mup 1.9%
Immunology revenue$801.0Mup 3.6%
Jardiance revenue$781.0Mup 84.2%
Trulicity revenue$601.0Mdown 15.0%
Taltz revenue$539.0Mdown 7.5%
Neuroscience revenue$384.0Mup 60.0%
United States revenue$15.1Bup 33.9%
Outside U.S. revenue$9.3Bup 47.0%
Europe revenue$4.5Bup 27.5%
Rest of world revenue$3.2Bup 89.9%
China revenue$947.0Mup 69.1%
Japan revenue$648.0Mup 16.8%

Earlier quarters

Eli Lilly and Company results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY202630 Sep 2026$24.40B+38.6%$7.22
Q2 FY202630 Jun 2026$22.97B+47.7%$7.94
Q1 FY202631 Mar 2026$19.80B+55.5%$8.26
Q4 FY202531 Dec 2025$19.29B+42.6%$7.39
Q3 FY202530 Sep 2025$17.60B+53.9%$6.21
Q2 FY202530 Jun 2025$15.56B+37.6%$6.29
Q1 FY202531 Mar 2025$12.73B+45.2%$3.06
Q4 FY202431 Dec 2024$13.53B+44.7%$4.88

More on Eli Lilly and Company: financial statements · revenue · earnings per share

LLY's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.